Latest Medicinal Cannabis Production News

ECS Botanics has launched the globally acclaimed Terphogz™ cannabis strains, including The Original Z™, into the Australian medicinal market, marking a strategic expansion of its premium product portfolio.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.

Cann Group Limited has resolved its legal dispute with Rua Biosciences, paving the way for new commercial agreements to supply medicinal cannabis products across Australia and New Zealand.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.

Cann Group Limited reported a positive operating cash flow for Q2 2024, driven by an R&D tax credit refund, while ramping up production and navigating pricing pressures in the medicinal cannabis market.